Dr Luis Raez speaks to ecancer about the latest developments on treating lung cancer that were presented at this year’s virtual ESMO.
He initially talks about the EMPOWER phase III study and explains the results of using a check point inhibitor with platinum based therapy for lung cancer patients. He further talks about PDL-1 targeted therapy in relation to immunotherapy and how immunotherapy has given better results with time.
He talks about two more studies regarding lung cancer, including EGFR therapies and the other targeted therapy drugs that are currently being used. In the end, he mentions some combination therapies and updated results of the PACIFIC trial. Dr Raez says that we now have better front-line therapies to deal with lung cancer with long-term results from all these clinical trials.